Report Highlights
-
The past decade has seen an explosion in knowledge concerning the immune system, and this is leading to a wealth of new drugs and procedures that selectively target the causes of immune diseases. As a result, we forecast that the worldwide market for drugs that treat immune disease will grow from an estimated $31.5 billion in 2002 to $47.1 billion by 2007. These diseases are one of the largest market opportunities for pharmaceutical and biotechnology companies since they are common, chronic and historic treatments have been largely ineffective.
-
The study examines the current market for the treatment of immune disease and then projects the effects of new technologies upon this market. It makes detailed, unbiased market forecasts for the period of 2002 to 2007 and profiles the major companies involved in treating immune disease.
INTRODUCTION
REASONS FOR THIS STUDY AND OBJECTIVES
This in-depth study examines recent commercial developments in immune disease treatments. The past decade has seen an explosion in knowledge concerning the immune system, and this is leading to a wealth of new drugs and procedures that selectively target the causes of immune diseases. As a result, we forecast that the worldwide market for drugs that treat immune disease will grow from an estimated $31.5 billion in 2002 to $47.1 billion by 2007. These diseases are one of the largest market opportunities for pharmaceutical and biotechnology companies since they are common, chronic and historic treatments have been largely ineffective.
The study examines the current market for the treatment of immune disease and then projects the effects of new technologies upon this market. It makes detailed, unbiased market forecasts for the period of 2002 to 2007 and profiles the major companies involved in treating immune disease.
AUDIENCE FOR THIS REPORT
This report offers a broad, yet detailed, overview of immune/autoimmune disease and the drugs that treat these diseases. Pharmaceutical and biotechnology companies working in the field will find the report useful in that it provides an unbiased assessment of the market potential of this field. In addition, the report provides an explanation of both the technology and the market effects of new technologies such as gene therapy, genomics, proteomics, high-throughput screening, and other technologies, upon immune disease.
Investors will find the report particularly interesting since it is rare to find a neutral appraisal of future prospects for the drug industry.
SCOPE AND CONTENT
This study surveys the market for small-molecule and biologic therapies for diseases caused by disorders of the immune system; therapies covered are either already used or will be used as medicine within the next 5 years (by the end of 2007). Promising drugs in the early stages of development are profiled, but the emphasis is strongly upon drugs that are either on the market, or will be on the market within the time frame of this study.
In addition to profiling drugs and explaining the mechanism by which these drugs achieve their efficacy, the report breaks out the major medical markets for immune disease.
This report does not cover drugs in pre-clinical testing. Due to governmental restrictions on drugs, these compounds will not be sold on the market for at least several years after 2007, if at all.
We do not cover medical devices (e.g., syringes for diabetics), or the direct costs of surgery to treat immune disease. We believe that the market dynamics of these products and services are dramatically different than the pharmaceutical market; customers interested in these markets would be better served by other BCC reports.
The report does not cover drugs that act to enhance the activity of the immune system against diseases such as cancer or opportunistic infections.
METHODOLOGY AND SOURCES
This report uses a combination of direct and indirect sources. Direct sources include interviews and conversations with scientists and analysts. Indirect sources include company news releases, governmental and non-governmental agencies, scientific journals and the popular press.
Sales were gathered from the most recently available data and represent worldwide sales of both branded and generic prescription drugs. In nearly all cases, this involved either first quarter sales figures or 2001 year-end reports. Sales for 2002 were based on year-to-date sales (generally through the second quarter) and estimates for the remaining two quarters of the year.
In some cases, (usually generic drugs), data was not available. Estimates were, therefore, made using patient populations, percentages treated with other drugs and average sales prices. In these cases it is clearly stated that these estimates are "rough".
Estimates of future worldwide growth depended primarily upon a baseline growth estimate of 8%. According to multiple estimates by research institutes, non-government and industry sources, overall pharmaceutical sales have grown at 8% over the past four decades. Sales in the U.S. have been growing much faster over the past few years, as evidenced by National Institute for Health Management's latest study, which estimated that U.S. prescription drug sales rose 17% last year. However, drug growth outside the U.S. has been much smaller. Furthermore, we predict that U.S. sales will revert to the mean on the back of numerous patent expirations.
Estimates for future sales growth within individual markets depended upon: patent expirations, percentage of the market penetrated, generic competition, competing drug classes, the introduction of new drugs, demographic growth and shifts, recent study results, and other variables. In each case where a forecast is made, the most important factors are listed. All figures for 2007 refer to the end of the year.
Sales are presented in millions of dollars, unless otherwise noted.
ANALYST CREDENTIALS
Robert J. Cyran has a Master's degree in Economics from the University of Birmingham, UK. For the past several years he has worked as an editor and biotechnology correspondent for various publications, among them Forbes Magazine and Worldlyinvestor.com. He is also the author of C-202R New Developments in Therapeutic Enzyme Inhibitors and Blockers.
Related Reports
Recent Reports
Gene Synthesis: Technologies and Global Markets
The global market for Gene Synthesis is estimated to increase from $2.0 billion in 2023 to reach $4.1 billion by 2028, at a compound annual growth rate (CAGR) of 15.8% from 2023 through 2028.
Flow Cytometry: Products, Technologies and Global Markets
The global market for flow cytometry products is expected to grow from $5.2 billion in 2023 to $8.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2029.
PEGylated Proteins Market
The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Top Trending Reports
ESG Trends in Chemical Industry
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
4D Imaging in Healthcare
The global market for 4D imaging in healthcare is estimated to grow from $8.1 billion in 2022 to $16.7 billion in 2027, with a compound annual growth rate (CAGR) of 15.3% for the period of 2022-2027.
AI in Mental Health: Global Market Outlook
The report provides an overview of the global AI in mental health market and analyzes market trends. Using 2021 as the base year, the report provides estimated market data for the forecast period, 2022-2027. Revenue forecasts for this period are segmented based on organization size, component, provider, type, industry, and geography. It also highlights major trends and challenges that affect the market and the vendor landscape.
Dental Restoration: Global Markets
The global dental restoration market should reach $16.1 billion by 2022 and $21.7 billion by 2027, with a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2022-2027.
Smart Waste Management Systems: Global Markets
The global smart waste management systems market should reach $451.5 billion by 2022 and $675.3 billion by 2027, with a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2022-2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More